APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Inactivated Vaccine Market Outlook and Growth Opportunities 2026

26 December 2025191 pages

Choose your research edition.

Industry ResearchInactivated Vaccine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Inactivated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Inactivated Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Inactivated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Inactivated Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Inactivated Vaccine market include Johnson & Johnson(U.S.), Merck & Co(U.S.), Pfizer(U.S.), GlaxoSmithKline(U.K.), Serum Institute of India Pvt(India), Sanofi Pasteur(France), MedImmune(U.S.), Emergent BioSolutions(U.S.) and CSL Limited(Australia), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Inactivated Vaccine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Inactivated Vaccine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Inactivated Vaccine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Inactivated Vaccine market.

Inactivated Vaccine Segment by Company

Johnson & Johnson(U.S.)

Merck & Co(U.S.)

Pfizer(U.S.)

GlaxoSmithKline(U.K.)

Serum Institute of India Pvt(India)

Sanofi Pasteur(France)

MedImmune(U.S.)

Emergent BioSolutions(U.S.)

CSL Limited(Australia)

Astellas Pharma(Japan)

Inactivated Vaccine Segment by Type

Children Inactivated Vaccine

Adult Inactivated Vaccine

Inactivated Vaccine Segment by Application

Hospital

Medical Center

Inactivated Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Inactivated Vaccine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Inactivated Vaccine key companies, revenue, market share, and recent developments.

3. To split the Inactivated Vaccine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Inactivated Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Inactivated Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Inactivated Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Inactivated Vaccine industry.

Chapter 3: Detailed analysis of Inactivated Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Inactivated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Inactivated Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Inactivated Vaccine Industry Trends Table 2. Inactivated Vaccine Industry Drivers Table 3. Inactivated Vaccine Industry Opportunities and Challenges Table 4. Inactivated Vaccine Industry Restraints Table 5. Global Inactivated Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Inactivated Vaccine Revenue Share by Company (2021-2026) Table 7. Global Inactivated Vaccine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Inactivated Vaccine Key Company Manufacturing Base & Headquarters Table 9. Global Inactivated Vaccine Company, Product Type & Application Table 10. Global Inactivated Vaccine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Inactivated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Children Inactivated Vaccine Table 15. Significant Companies of Adult Inactivated Vaccine Table 16. Global Inactivated Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Inactivated Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Inactivated Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Inactivated Vaccine Sales Value Share by Type (2021-2026) Table 20. Global Inactivated Vaccine Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Medical Center Table 23. Global Inactivated Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Inactivated Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Inactivated Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Inactivated Vaccine Sales Value Share by Application (2021-2026) Table 27. Global Inactivated Vaccine Sales Value Share by Application (2027-2032) Table 28. Global Inactivated Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Inactivated Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Inactivated Vaccine Sales Value Share by Region (2021-2026) Table 31. Global Inactivated Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Inactivated Vaccine Sales Value Share by Region (2027-2032) Table 33. Global Inactivated Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Inactivated Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Inactivated Vaccine Sales Value Market Share by Country (2021-2026) Table 36. Global Inactivated Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Inactivated Vaccine Sales Value Market Share by Country (2027-2032) Table 38. Johnson & Johnson(U.S.) Company Information Table 39. Johnson & Johnson(U.S.) Business Overview Table 40. Johnson & Johnson(U.S.) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio Table 42. Johnson & Johnson(U.S.) Recent Development Table 43. Merck & Co(U.S.) Company Information Table 44. Merck & Co(U.S.) Business Overview Table 45. Merck & Co(U.S.) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Merck & Co(U.S.) Inactivated Vaccine Product Portfolio Table 47. Merck & Co(U.S.) Recent Development Table 48. Pfizer(U.S.) Company Information Table 49. Pfizer(U.S.) Business Overview Table 50. Pfizer(U.S.) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Pfizer(U.S.) Inactivated Vaccine Product Portfolio Table 52. Pfizer(U.S.) Recent Development Table 53. GlaxoSmithKline(U.K.) Company Information Table 54. GlaxoSmithKline(U.K.) Business Overview Table 55. GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio Table 57. GlaxoSmithKline(U.K.) Recent Development Table 58. Serum Institute of India Pvt(India) Company Information Table 59. Serum Institute of India Pvt(India) Business Overview Table 60. Serum Institute of India Pvt(India) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio Table 62. Serum Institute of India Pvt(India) Recent Development Table 63. Sanofi Pasteur(France) Company Information Table 64. Sanofi Pasteur(France) Business Overview Table 65. Sanofi Pasteur(France) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio Table 67. Sanofi Pasteur(France) Recent Development Table 68. MedImmune(U.S.) Company Information Table 69. MedImmune(U.S.) Business Overview Table 70. MedImmune(U.S.) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. MedImmune(U.S.) Inactivated Vaccine Product Portfolio Table 72. MedImmune(U.S.) Recent Development Table 73. Emergent BioSolutions(U.S.) Company Information Table 74. Emergent BioSolutions(U.S.) Business Overview Table 75. Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio Table 77. Emergent BioSolutions(U.S.) Recent Development Table 78. CSL Limited(Australia) Company Information Table 79. CSL Limited(Australia) Business Overview Table 80. CSL Limited(Australia) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. CSL Limited(Australia) Inactivated Vaccine Product Portfolio Table 82. CSL Limited(Australia) Recent Development Table 83. Astellas Pharma(Japan) Company Information Table 84. Astellas Pharma(Japan) Business Overview Table 85. Astellas Pharma(Japan) Inactivated Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio Table 87. Astellas Pharma(Japan) Recent Development Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Inactivated Vaccine Product Image Figure 2. Global Inactivated Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inactivated Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Inactivated Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Children Inactivated Vaccine Image Figure 8. Adult Inactivated Vaccine Image Figure 9. Global Inactivated Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Inactivated Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Inactivated Vaccine Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Medical Center Image Figure 14. Global Inactivated Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Inactivated Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Inactivated Vaccine Sales Value Share by Application (2021-2032) Figure 17. Global Inactivated Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Inactivated Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 20. North America Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 26. South America Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Inactivated Vaccine Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Inactivated Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Inactivated Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Children Inactivated Vaccine
  • Adult Inactivated Vaccine
Applications
  • Hospital
  • Medical Center
Companies covered
  • Johnson & Johnson(U.S.)
  • Merck & Co(U.S.)
  • Pfizer(U.S.)
  • GlaxoSmithKline(U.K.)
  • Serum Institute of India Pvt(India)
  • Sanofi Pasteur(France)
  • MedImmune(U.S.)
  • Emergent BioSolutions(U.S.)
  • CSL Limited(Australia)
  • Astellas Pharma(Japan)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Inactivated Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Inactivated Vaccine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Inactivated Vaccine Market Dynamics
  1. 2.1 Inactivated Vaccine Industry Trends
  2. 2.2 Inactivated Vaccine Industry Drivers
  3. 2.3 Inactivated Vaccine Industry Opportunities and Challenges
  4. 2.4 Inactivated Vaccine Industry Restraints
3 Inactivated Vaccine Market by Company
  1. 3.1 Global Inactivated Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Inactivated Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Inactivated Vaccine Company Ranking (2024-2026)
  4. 3.4 Global Inactivated Vaccine Company Manufacturing Base and Headquarters
  5. 3.5 Global Inactivated Vaccine Company Product Type and Application
  6. 3.6 Global Inactivated Vaccine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Inactivated Vaccine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Inactivated Vaccine Market by Type
  1. 4.1 Inactivated Vaccine Type Introduction
  2. 4.1.1 Children Inactivated Vaccine
  3. 4.1.2 Adult Inactivated Vaccine
  4. 4.2 Global Inactivated Vaccine Sales Value by Type
  5. 4.2.1 Global Inactivated Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Inactivated Vaccine Sales Value by Type (2021-2032)
  7. 4.2.3 Global Inactivated Vaccine Sales Value Share by Type (2021-2032)
5 Inactivated Vaccine Market by Application
  1. 5.1 Inactivated Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Medical Center
  4. 5.2 Global Inactivated Vaccine Sales Value by Application
  5. 5.2.1 Global Inactivated Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Inactivated Vaccine Sales Value by Application (2021-2032)
  7. 5.2.3 Global Inactivated Vaccine Sales Value Share by Application (2021-2032)
6 Inactivated Vaccine Regional Value Analysis
  1. 6.1 Global Inactivated Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Inactivated Vaccine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Inactivated Vaccine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Inactivated Vaccine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Inactivated Vaccine Sales Value (2021-2032)
  7. 6.3.2 North America Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Inactivated Vaccine Sales Value (2021-2032)
  10. 6.4.2 Europe Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Inactivated Vaccine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Inactivated Vaccine Sales Value (2021-2032)
  16. 6.6.2 South America Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Inactivated Vaccine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Inactivated Vaccine Sales Value Share by Country, 2025 VS 2032
7 Inactivated Vaccine Country-level Value Analysis
  1. 7.1 Global Inactivated Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Inactivated Vaccine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Inactivated Vaccine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Inactivated Vaccine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Inactivated Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Inactivated Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Inactivated Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson(U.S.)
  2. 8.1.1 Johnson & Johnson(U.S.) Company Information
  3. 8.1.2 Johnson & Johnson(U.S.) Business Overview
  4. 8.1.3 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio
  6. 8.1.5 Johnson & Johnson(U.S.) Recent Developments
  7. 8.2 Merck & Co(U.S.)
  8. 8.2.1 Merck & Co(U.S.) Company Information
  9. 8.2.2 Merck & Co(U.S.) Business Overview
  10. 8.2.3 Merck & Co(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co(U.S.) Inactivated Vaccine Product Portfolio
  12. 8.2.5 Merck & Co(U.S.) Recent Developments
  13. 8.3 Pfizer(U.S.)
  14. 8.3.1 Pfizer(U.S.) Company Information
  15. 8.3.2 Pfizer(U.S.) Business Overview
  16. 8.3.3 Pfizer(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer(U.S.) Inactivated Vaccine Product Portfolio
  18. 8.3.5 Pfizer(U.S.) Recent Developments
  19. 8.4 GlaxoSmithKline(U.K.)
  20. 8.4.1 GlaxoSmithKline(U.K.) Company Information
  21. 8.4.2 GlaxoSmithKline(U.K.) Business Overview
  22. 8.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio
  24. 8.4.5 GlaxoSmithKline(U.K.) Recent Developments
  25. 8.5 Serum Institute of India Pvt(India)
  26. 8.5.1 Serum Institute of India Pvt(India) Company Information
  27. 8.5.2 Serum Institute of India Pvt(India) Business Overview
  28. 8.5.3 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio
  30. 8.5.5 Serum Institute of India Pvt(India) Recent Developments
  31. 8.6 Sanofi Pasteur(France)
  32. 8.6.1 Sanofi Pasteur(France) Company Information
  33. 8.6.2 Sanofi Pasteur(France) Business Overview
  34. 8.6.3 Sanofi Pasteur(France) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio
  36. 8.6.5 Sanofi Pasteur(France) Recent Developments
  37. 8.7 MedImmune(U.S.)
  38. 8.7.1 MedImmune(U.S.) Company Information
  39. 8.7.2 MedImmune(U.S.) Business Overview
  40. 8.7.3 MedImmune(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MedImmune(U.S.) Inactivated Vaccine Product Portfolio
  42. 8.7.5 MedImmune(U.S.) Recent Developments
  43. 8.8 Emergent BioSolutions(U.S.)
  44. 8.8.1 Emergent BioSolutions(U.S.) Company Information
  45. 8.8.2 Emergent BioSolutions(U.S.) Business Overview
  46. 8.8.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio
  48. 8.8.5 Emergent BioSolutions(U.S.) Recent Developments
  49. 8.9 CSL Limited(Australia)
  50. 8.9.1 CSL Limited(Australia) Company Information
  51. 8.9.2 CSL Limited(Australia) Business Overview
  52. 8.9.3 CSL Limited(Australia) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 CSL Limited(Australia) Inactivated Vaccine Product Portfolio
  54. 8.9.5 CSL Limited(Australia) Recent Developments
  55. 8.10 Astellas Pharma(Japan)
  56. 8.10.1 Astellas Pharma(Japan) Company Information
  57. 8.10.2 Astellas Pharma(Japan) Business Overview
  58. 8.10.3 Astellas Pharma(Japan) Inactivated Vaccine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio
  60. 8.10.5 Astellas Pharma(Japan) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst